10 results on '"Yuce, Kunter"'
Search Results
2. Could the Long-Term Oncological Safety of Laparoscopic Surgery in Low-Risk Endometrial Cancer also Be Valid for the High-Intermediate- and High-Risk Patients? A Multi-Center Turkish Gynecologic Oncology Group Study Conducted with 2745 Endometrial Cancer Cases. (TRSGO-End-001)
- Author
-
Vardar, Mehmet Ali, Guzel, Ahmet Baris, Taskin, Salih, Gungor, Mete, Ozgul, Nejat, Salman, Coskun, Kucukgoz-Gulec, Umran, Khatib, Ghanim, Taskiran, Cagatay, Dünder, Ilkkan, Ortac, Firat, Yuce, Kunter, Terek, Cosan, Simsek, Tayup, Ozsaran, Aydın, Onan, Anil, Coban, Gonca, Topuz, Samet, Demirkiran, Fuat, and Takmaz, Ozguc
- Subjects
ENDOMETRIAL cancer ,GYNECOLOGIC oncology ,LAPAROSCOPIC surgery ,ENDOMETRIAL surgery ,PROGRESSION-free survival ,ABDOMINAL surgery - Abstract
This study was conducted to compare the long-term oncological outcomes of laparotomy and laparoscopic surgeries in endometrial cancer under the light of the 2016 ESMO-ESGO-ESTRO risk classification system, with particular focus on the high-intermediate- and high-risk categories. Using multicentric databases between January 2005 and January 2016, disease-free and overall survivals of 2745 endometrial cancer cases were compared according to the surgery route (laparotomy vs. laparoscopy). The high-intermediate- and high-risk patients were defined with respect to the 2016 ESMO-ESGO-ESTRO risk classification system, and they were analyzed with respect to differences in survival rates. Of the 2745 patients, 1743 (63.5%) were operated by laparotomy, and the remaining were operated with laparoscopy. The total numbers of high-intermediate- and high-risk endometrial cancer cases were 734 (45%) patients in the laparotomy group and 307 (30.7%) patients in the laparoscopy group. Disease-free and overall survivals were not statistically different when compared between laparoscopy and laparotomy groups in terms of low-, intermediate-, high-intermediateand high-risk endometrial cancer. In conclusion, regardless of the endometrial cancer risk category, long-term oncological outcomes of the laparoscopic approach were found to be comparable to those treated with laparotomy. Our results are encouraging to consider laparoscopic surgery for high-intermediate- and high-risk endometrial cancer cases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging.
- Author
-
Gultekin, Melis, Guler, Ozan Cem, Yuce Sari, Sezin, Akkus Yildirim, Berna, Onal, Cem, Celik, Husnu, Yuce, Kunter, Ayhan, Ali, Arik, Zafer, Kose, Fatih, Altundag, Ozden, Zoto Mustafayev, Teuta, Atalar, Banu, Bolukbasi, Yasemin, and Yildiz, Ferah
- Subjects
ENDOMETRIAL cancer ,ENDOMETRIAL surgery ,EXTERNAL beam radiotherapy ,OVERALL survival ,CANCER patients ,SURGICAL margin ,UTERINE surgery ,RESEARCH ,RESEARCH evaluation ,RESEARCH methodology ,GYNECOLOGY ,CANCER relapse ,MEDICAL cooperation ,EVALUATION research ,RISK assessment ,UTERUS ,TREATMENT effectiveness ,TUMOR classification ,COMPARATIVE studies ,ENDOMETRIAL tumors ,RADIOTHERAPY ,RADIOISOTOPE brachytherapy ,ONCOLOGY ,TUMOR grading ,MEDICAL societies ,STANDARDS - Abstract
In this study, 683 patients with endometrial cancer (EC) after comprehensive surgical staging were classified into four risk groups as low (LR), intermediate (IR), high-intermediate (HIR) and high-risk (HR), according to the recent consensus risk grouping. Patients with disease confined to the uterus, ≥50% myometrial invasion (MI) and/or grade 3 histology were treated with vaginal brachytherapy (VBT). Patients with stage II disease, positive/close surgical margins or extra-uterine extension were treated with external beam radiotherapy (EBRT)±VBT. The median follow-up was 56 months. The overall survival (OS) was significantly different between LR and HR groups, and there was a trend between LR and HIR groups. Relapse-free survival (RFS) was significantly different between LR and HIR, LR and HR and IR and HR groups. There was no significant difference in OS and RFS rates between the HIR and HR groups. In HR patients, the OS and RFS rates were significantly higher in stage IB - grade 3 and stage II compared to stage III and non-endometrioid histology without any difference between the two uterine-confined stages and between stage III and non-endometrioid histology. The current risk grouping does not clearly discriminate the HIR and IR groups. In patients with comprehensive surgical staging, a further risk grouping is needed to distinguish the real HR group.Impact statementWhat is already known on this subject? The standard treatment for endometrial cancer (EC) is surgery and adjuvant radiotherapy (RT) and/or chemotherapy is recommended according to risk factors. The recent European Society for Medical Oncology (ESMO), European Society of Gynaecological Oncology (ESGO) and European Society for Radiotherapy and Oncology (ESTRO) guideline have introduced a new risk group. However, the risk grouping is still quite heterogeneous.What do the results of this study add? This study demonstrated that the current risk grouping recommended by ESMO-ESGO-ESTRO does not clearly discriminate the intermediate risk (IR) and high-intermediate risk (HIR) groups.What are the implications of these findings for clinical practice and/or further research? Based on the results of this study, a new risk grouping can be made to discriminate HIR and IR groups clearly in patients with comprehensive surgical staging. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Comparison of Mayo and Milwaukee Risk Stratification Models for Predicting Lymph Node Metastasis in Endometrial Cancer.
- Author
-
Boyraz, Gokhan, Atalay, Fatma Oz, Salman, Mehmet Coskun, Usubutun, Alp, Erturk, Anil, Gultekin, Murat, Ozgul, Nejat, and Yuce, Kunter
- Abstract
Objective: The aim of this study was to compare Mayo and Milwaukee risk stratification models for predicting lymphatic dissemination in patients with endometrial cancer (EC). Methods: A total of 904 patients with EC underwent surgical treatment between 2004 and 2016 at Hacettepe University Hospital, and clinicopathological data of patients were retrieved from the computerized database of the Hacettepe University. Patients who did not undergo lymphadenectomy and who had nonendometrioid histology, stage-IV disease, and synchronous epithelial ovarian and EC were excluded. All slides of the cases were reviewed by the same gynecologic pathology subspecialist. Results: The study group consisted of 307 consecutive patients with a mean age of 59.4 years (range, 26–86 years). Lymph node metastasis was detected in 28 subjects (9.1%). Primary tumor diameter, depth of myometrial invasion, lymphovascular space invasion, and cervical stromal and glandular involvement were associated with lymph node metastasis. Patients with low-risk histological features based on Mayo risk stratification system in our study group had a 0% rate of lymph node positivity. However, of the 28 patients with lymph node metastasis, 3 (10.7%) had low-risk features based on Milwaukee model. The sensitivity, specificity, false negative rate (FNR) and false positive rate of Mayo and Milwaukee risk stratification models for predicting lymphatic dissemination among women with endometrioid EC were 100%, 27.3%, 0%, and 72.7%; and 89.3%, 61.3%, 10.7%, and 38.7%, respectively. Conclusions: Although Milwaukee risk stratification model had a lower false positive rate and can decrease the number of lymphadenectomies, FNR of this new model was found as 10.7% in the present study. Furthermore, we found that Mayo model had a lower FNR and higher sensitivity. Therefore, Mayo model still looks more beneficial to predict lymph node metastasis in patients with endometrioid EC and Milwaukee risk stratification model still requires external validation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Oncological Outcomes of Stage II Endometrial Cancer: A Retrospective Analysis of 250 Cases.
- Author
-
Ozgul, Nejat, Boyraz, Gokhan, Salman, Mehmet Coskun, Gultekin, Murat, Yuce, Kunter, Ibrahimov, Akbar, Erturk, Anil, Gungorduk, Kemal, Gulseren, Varol, Sanci, Muzaffer, Turkmen, Osman, Karalok, Alper, Kimyon, Gunsu, Turan, Taner, Ozkan, Nazlı Topfedaisi, Meydanlı, Mehmet Mutlu, Gungor, Tayfun, Ayik, Hulya, and Simsek, Tayup
- Abstract
Objective: The aim of this study was to investigate the effect of different surgical approaches, adjuvant therapy, and pathological characteristics on oncological outcomes in patients with 2009 International Federation of Gynecology and Obstetrics (FIGO) stage II endometrial cancer (EC). Methods: A multicenter, retrospective department database review was performed to identify patients with FIGO 2009 stage II EC who underwent surgical staging between 2002 and 2015 at 5 gynecologic oncology centers in Turkey. Results: Original pathology reports of 4867 patients who underwent surgical treatment for EC were analyzed. The study group consisted of 250 FIGO stage II patients. Of these patients, 203 (81.2%) had endometrioid and 47 (18.8%) had nonendometrioid histologic subtype of EC. Whereas 199 patients (79.6%) underwent type I hysterectomy, the remaining 51 patients (20.4%) underwent radical hysterectomy. Of the 250 patients, 208 patients (83.2%) had adjuvant therapy including radiotherapy (pelvic external beam radiotherapy and/or vaginal brachytherapy [VBT]) and/or platinum-based chemotherapy. Disease recurred in 29 patients (11.6%). The 5-year disease-free survival (DFS) and overall survival (OS) for the entire cohort were 82%and 85%, respectively. Multivariate analysis showed that only adjuvant treatment (P = 0.001; hazard ratio, 4.02; 95% confidence interval, 1.72-9.36) was significantly associated with DFS. According to multivariate analysis, only age older than 60 years (P =0.01; hazard ratio, 3.03; 95% confidence interval, 1.3-7.04) was identified as an independent risk factor for OS. However, there were no differences in OS when evaluated by grade, histology, tumor size, type of hysterectomy, or adjuvant treatment. Conclusions: In stage II EC, adjuvant external beam radiotherapy T VBT were associated with increased DFS but not OS. However, the benefit of VBT alone on DFS could not be demonstrated. Only age was an independent risk factor for OS. Type of hysterectomy and histologic subtype of the tumor for patients with uterus-confined disease improved neither DFS nor OS in our study group. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Incidence of Lymph Node Metastasis in Surgically Staged FIGO IA G1/G2 Endometrial Cancer With a Tumor Size of More Than 2 cm.
- Author
-
Boyraz, Gokhan, Salman, Mehmet Coskun, Gultekin, Murat, Basaran, Derman, Cagan, Murat, Ozgul, Nejat, and Yuce, Kunter
- Abstract
Objective: The study aims to investigate effect of tumor size on lymphatic spread in patients with low-risk endometrial cancer (EC). Methods: This study included patients with EC who underwent staging surgery with systematic lymphadenectomy between 2002 and 2015 at the Hacettepe University Hospital. Patients with grade 1 or 2 endometrioid type tumor who had 50%or lower myometrial invasion were included. Patients who had no myometrial invasion or had uterine high-risk features (nonendometrioid histology, grade 3, and deep myometrial invasion) were excluded. Results: The study group consisted of 191 patients, and the mean age of the patients was 57.8 years. Of these patients, 124 (64.9%) had tumor size of more than 2 cm and 67 (35.1%) had tumor size of 2 cm or less. Lymph node metastasis was detected in 12 (9.7%) of the 124 patients with tumor size of more than 2 cm. On the other hand, none of the 67 patients (0%) with tumor size of 2 cm or less was found to have lymphatic involvement. Of the factors analyzed for correlation with lymph node metastasis in patients with low-risk EC, the presence of lymphovascular space invasion (LVSI) and primary tumor size were found to be significant predictors of lymphatic spread in univariate analysis (P < 0.001 and P = 0.009, respectively). In multivariate analysis, tumor size (odds ratio, 6.86; 95% confidence interval, 1.007-infinite; P < 0.05) and LVSI (odds ratio, 14.261; 95% confidence interval, 3.4-59.6; P < 0.001) were 2 independent predictors associated with lymphatic involvement. Conclusions: Our trial supports that tumor size of more than 2 cm and LVSI are 2 independent factors for lymph node metastasis in patients with low-risk EC. Both factors can be used together to select patients with traditional low-risk histologic features who would absolutely benefit from lymph node dissection. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Assessment of Cervicovaginal Cancer Antigen 125 Levels: A Preliminary Study for Endometrial Cancer Screening.
- Author
-
Calis, Pinar, Yuce, Kunter, Basaran, Derman, and Salman, Coskun
- Subjects
- *
MEDICAL screening , *BLOOD serum analysis , *CA 125 test , *ENDOMETRIAL surgery , *ADENOCARCINOMA , *CERVIX uteri , *SECRETION , *TUMOR antigens , *VAGINA , *CASE-control method , *ENDOMETRIAL tumors , *RECEIVER operating characteristic curves , *CARCINOMA in situ , *EARLY detection of cancer , *DIAGNOSIS ,DIAGNOSIS of endometrial cancer - Abstract
Aim: We primarily aimed to compare the levels of serum and cervicovaginal cancer antigen 125 (CA 125) in women with and without endometrial carcinoma in order to reveal whether cervicovaginal CA 125 could be used as a non-invasive method.Methods: A preliminary case-control study was designed. The study group consisted of patients who were operated for endometrial adenocarcinoma or endometrial intraepithelial neoplasia. The control group consisted of patients who underwent surgery for benign gynecological diseases. Serum and cervicovaginal secretions were immediately collected before surgery to compare levels of CA 125.Results: The mean cervicovaginal CA 125 levels in patients with endometrial cancer and controls were 1,598.1 ± 1,691.1 versus 947.0 ± 1,282.7 U/ml, respectively (p = 0.016). Whereas area under receiver operating characteristic curve was 0.62 for serum CA 125, it was 0.68 for cervicovaginal CA 125. The optimal threshold of CA 125 in cervicovaginal secretion was calculated to be 575 U/ml, which detected endometrial precancer or cancer with sensitivity of 78% and specificity of 57%. The positive and negative predictive values for this threshold were 38.7 and 88.2%, respectively.Conclusion: In conclusion, detection of CA 125 in cervicovaginal secretion has a potential role for the non-invasive screening of endometrial precancers and cancers. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
8. Intraoperative Ex Vivo High-Resolution Sonography.
- Author
-
Basaran, Derman, Salman, Mehmet Coskun, Boyraz, Gokhan, Akata, Deniz, Ozmen, Mustafa, Usubutun, Alp, Ozgul, Nejat, and Yuce, Kunter
- Published
- 2015
- Full Text
- View/download PDF
9. Assessing the Quality of Life in Patients With Endometrial Cancer Treated With Adjuvant Radiotherapy.
- Author
-
Karabuga, Havva, Gultekin, Melis, Tulunay, Gokhan, Yuce, Kunter, Ayhan, Ali, Yuce, Deniz, and Yildiz, Ferah
- Published
- 2015
- Full Text
- View/download PDF
10. Role of postmenopausal bleeding pattern and women's age in the prediction of endometrial cancer.
- Author
-
Salman, Mehmet C., Bozdag, Gurkan, Dogan, Selen, and Yuce, Kunter
- Subjects
ENDOMETRIAL tumors ,ACADEMIC medical centers ,AGE distribution ,BIOPSY ,CHI-squared test ,CONFIDENCE intervals ,ENDOSCOPIC ultrasonography ,EPIDEMIOLOGY ,FISHER exact test ,HEMORRHAGE ,LONGITUDINAL method ,MULTIVARIATE analysis ,T-test (Statistics) ,LOGISTIC regression analysis ,DATA analysis ,BODY mass index ,POSTMENOPAUSE ,DATA analysis software ,DESCRIPTIVE statistics ,TUMOR risk factors - Abstract
Background Women with postmenopausal bleeding should be evaluated efficiently to exclude endometrial carcinoma. Aims To estimate the risk of endometrial cancer using individual case characteristics among women with postmenopausal bleeding in whom the endometrial thickness is >4 mm. Methods Women with postmenopausal bleeding underwent clinical evaluation followed by transvaginal ultrasonography and endometrial biopsy. Clinical evaluation included age, body mass index, duration of menopause, number of bleeding episodes and amount of bleeding. Results This study included 142 women, and endometrial carcinoma was found in 18 (12.7%). Older age, higher body mass index, longer duration of menopause, longer lasting bleeding episodes, higher amount of bleeding and recurrent bleeding episodes were the clinical characteristics associated with endometrial cancer. However, multivariate analysis revealed >55 years of age during postmenopausal bleeding, history of recurrent bleeding episodes and bleeding exceeding 5 pads per day in each episode as significant parameters, which predicted the presence of endometrial cancer among women with postmenopausal bleeding. Conclusions Prompt evaluation is required in women with postmenopausal bleeding to exclude endometrial cancer. Transvaginal ultrasonography is a reasonable first-line approach, and invasive sampling is required when ultrasonographic endometrial thickness is above 4 mm. However, about 90% of women with postmenopausal bleeding will finally be found to have a nonmalignant condition. Therefore, women who are at increased cancer risk should further be distinguished. This may be achieved using individual patient characteristics that result in a more accurate evaluation strategy with lower rates of unnecessary invasive procedures. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.